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ABSTRACT
Objectives: To estimate the medical expenditure associated with osteo-
porotic hip fracture in elderly Korean women from insurer’s perspective.
Methods: All claim records of women aged50 years and diagnosed with
hip fracture from 2002 to 2004 were obtained from the Korean National
Health Insurance. The ﬁrst 6 months were considered a “window period”
during which patients with fractures were deﬁned as incident cases if their
initial records of visit or admission were observed after June 30, 2002. We
included only those with claim records showing diagnosis of osteoporosis
or prescription for antiosteoporosis drugs. For each patient, we calculated
the cumulative claims amount related to the initial and follow-up treat-
ment for 2 years after fracture.
Results: A total of 22,247 patients were identiﬁed during 2.5 years.
During the ﬁrst year of fracture, an average of 3.28 visits and 0.97
admissions were recorded; during the second year, 0.35 visits and
0.02 admissions were recorded. The 2-year cost per patient was
KRW3,175,467, 97.4% of which was incurred during ﬁrst year.
Conclusion: Exploring the economic burden of osteoporotic hip fracture
in the elderly women is expected to motivate policymakers and clinicians
to adopt effective treatment options for the disease prevention and expen-
diture control.
Keywords: claims data, cost of illness, hip fracture, osteoporosis.
Introduction
The availability of advanced medical technologies and the
improved economic status has increased life expectancy and the
proportion of the aging population. This has increased the preva-
lence of geriatric diseases, resulting in a corresponding increase in
medical expenditure. In particular, the increase in the life expect-
ancy of women is greater than that of men; consequently, there is
an increase in the prevalence of osteoporosis, which is a common
degenerative disease encountered in elderly women [1].
Osteoporosis leads to fractures, resulting in increased morbidity
and an abrupt decrease in the quality of life [2]. Therefore,
osteoporosis has been addressed as a major health issue of the
elderly female population [1]. Hip fracture is widely recognized
as a major sequel of osteoporosis and is associated with high
treatment expenses [3,4]. Additionally, hip fracture represents a
major cause of disability in the elderly population [5,6] and
increases the mortality rate by approximately 12% to 20%
within 1 year of onset [7,8].
With the growing prevalence of osteoporotic hip fractures in
the elderly female population, studies have been conducted in the
developed world to estimate the cost of illness of osteoporotic hip
fractures [8]. Although Korea has witnessed an increase in the
aging population and the prevalence of osteoporotic fractures
parallel to that in developed countries, active diagnosis and treat-
ment of osteoporosis have not been implemented effectively.
Furthermore, there is a lack of epidemiological data on
osteoporosis as well as paucity of information on the cost of
illness of osteoporosis-related fractures.
Estimating the socioeconomic cost of a disease can facilitate
the prioritization of relevant policies by recognizing the relative
importance and severity of the disease, allow the establishment of
efﬁcient treatment strategies by identifying medical services that
impose a high economic burden, and provide basic data for
evaluating relatively cost-effective treatment alternatives. There-
fore, many countries have generated such information and have
been utilizing it for decision-making in resource allocation per-
taining to medical services.
The present study was conducted to determine the national
health insurance (NHI) perspective of the economic burden of
osteoporotic hip fractures by estimating the per patient and total
national medical expenditure for hip fracture treatment among
Korean women aged 50 years. This information is expected
to be useful for promoting aggressive treatment of geriatric
osteoporosis and to facilitate the decision-making process for
identifying health-related priorities by highlighting the relative




This study estimated the direct medical costs of osteoporotic hip
fractures based on an “incidence-based approach” [9]. Patients
with osteoporotic hip fractures were retrospectively followed
for up to 2 years to estimate the additional treatment costs from
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the insurer’s perspective. This study adopted a top-down
approach to determine the treatment expenses of all cases of hip
fracture in Korean women aged 50 years and to estimate the
average cost of treatment for individual patients [10,11].
Study Subjects and Data Sources
Study subjects comprised women aged 50 years who suffered
osteoporotic hip fractures during the 2.5-year interval (July
2002–December 2004) and were selected. To see the selection
process, see Estimating Medical Expenditure Associated with
Osteoporotic Hip Fracture in Elderly Korean Women Based on
the National Health Insurance Claims Database 2002–2004
Value in Health Supporting Information, Figure S1 at: http://
www.ispor.org/Publications/value/ViHsupplementary/ViH12s3_
Kang.asp.
Step 1: identiﬁcation of prevalent cases. Women aged 50 years
with1 insurance claim record bearing the diagnosis code of hip
fracture between January 1, 2002 and December 31, 2004 were
identiﬁed. To see the table, see Estimating Medical Expenditure
Associated with Osteoporotic Hip Fracture in Elderly Korean
Women Based on the National Health Insurance Claims Database
2002–2004 Value in Health Supporting Information, Table S1
at: http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_ Kang.asp.
Step 2: identiﬁcation of incident cases. The ﬁrst 6 months
(January 1, 2002 to June 30, 2002) was established as a window
period during which patients with 1 claim for the use of
medical services for hip fracture were excluded from the study.
Patients who had not received fracture-related treatment during
the previous 6 months but placed such claims subsequently could
be considered as incident cases.
Step 3: exclusion of patients with multiple fractures. To estimate
expenditure related to only hip fractures, patients with claims
records of the use of medical services for diagnosis of other
fractures in addition to hip fracture were excluded from the study
as they were considered as cases of compound fracture.
Step 4: exclusion of patients with high-cost diseases or drug-
induced osteoporosis. To prevent the erroneous inclusion of
medical expenditure related to underlying diseases other than
fracture, patients with cancer and end-stage renal failure were
excluded because these conditions represent high-cost illnesses,
based on consultations with clinicians.
Additionally, to restrict study subjects to patients suffering
from fracture due to geriatric osteoporosis, patients with non-
osteoporotic fractures derived from trafﬁc accidents, endocrine
diseases (International Classiﬁcation of Diseases-10 codes: E05~,
E10~, E21~, E23~, or E24~), or drug-induced osteoporosis
(M804~, M814~, or M816~) were excluded.
Step 5: restriction of study subjects to patients with osteoporotic
fractures. The study included only those patients whose claims
records showed at least a single diagnosis of osteoporosis (M80~
or M81~) or at least one prescription for antiosteoporosis drugs
reimbursed (alendronate, etidronate, raloxifen, risedronate, and
salcatonin) during the 3-year observation period.
For each study subject, the ﬁrst fracture-related hospital
admission or visit was deﬁned as the time point of incidence of
hip fracture. Follow-up treatments after the incidence were
deﬁned as claims satisfying criteria 1 and 2.
• Criteria 1: claims with the same diagnosis code as the ﬁrst
hospital admission or visit for hip fracture
• Criteria 2: claims indicating the medical department as the
department of orthopedic surgery.
Data Analysis
The average per capita and total national insurance-covered
medical costs for treating incident hip fractures during the ﬁrst
and second years after fracture occurrence were estimated for
5-year age groups. If only patients who survived throughout the
2-year period were included in the estimation of per capita
expenditure, the medical expenses immediately before death due
to fracture-related complications would not be reﬂected. To over-
come such issues, medical expenses incurred as long as a patient
survived during the 2-year period were included while calculating
the average expenses. For example, in patients who survived
for 6 months after fracture, the expenses up to month 6 were
reﬂected. In other words, the per capita average medical expenses
of survivors were calculated for each month, and the monthly
expenses were added up for months 1 to 12 and 13 to 24; ﬁnally,
the per capita average medical expenditure was estimated for the
ﬁrst and second years after fracture. All costs were expressed in
2006 monetary value.
Study Results
A total of 22,247 female patients, aged 50 years and with hip
fracture, satisﬁed all the study inclusion and exclusion criteria
during the 2.5 years. The annual incidence rate of osteoporotic
hip fracture was calculated for each age group, by dividing the
annual incidence of hip fracture cases by the total number of
population in 2003. The incidence rate for women aged 50
years was 15.4 cases per 10,000 populations. It increases with
age, from 0.9 for 50 to 54 years of age to 78.4 for 85 years of
age. To see the table, see Estimating Medical Expenditure Asso-
ciated with Osteoporotic Hip Fracture in Elderly Korean Women
Based on the National Health Insurance Claims Database 2002–
2004 Value in Health Supporting Information, Table S2 at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_ Kang.asp. The per capita average number of hospital-
izations and outpatient visits was 0.97and 3.28 during the ﬁrst
year. With increase in age, the proportion of inpatient care
increased, although that of outpatient care decreased. During the
second year, the average per capita number of hospitalizations
and outpatient visits was 0.02 and 0.35. With increase in age, no
linear upward or downward trends in the use of medical services
was observed during the second year.
The total insurance-covered medical expenditure for treat-
ment of fracture patients across Korea amounted to KRW74.76
billion during the ﬁrst year; inpatient medical expenses stood at
KRW72.20 billion and outpatient expenses were KRW2.56
billion. The total insurance-covered medical expenditure during
the second year amounted to KRW1.34 billion (inpatient care,
KRW1.06 billion; outpatient care, KRW0.29 billion). The com-
bined expenditure for the ﬁrst and second years was KRW76.11
billion. The highest combined expenditure was incurred by age
groups 75 to 79 (KRW17.76 billion), 80 to 84 (KRW15.81
billion), and 70 to 74 (KRW14.63 billion). To see the table, see
Estimating Medical Expenditure Associated with Osteoporotic
Hip Fracture in Elderly Korean Women Based on the National
Health Insurance Claims Database 2002–2004 Value in Health
Supporting Information, Table S3 at: http://www.ispor.org/
Publications/value/ViHsupplementary/ViH12s3_ Kang.asp.
The average medical expenditure incurred by each patient
was KRW3,094,439 during the ﬁrst year and KRW81,028 during
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the second year, amounting to a cumulative expenditure of
KRW3,175,467. During the ﬁrst year, inpatient medical expenses
accounted for 96.0% (KRW2,979,109) of the total costs
incurred, although they accounted for 78.6% during the second
year. To see the table, see Estimating Medical Expenditure Asso-
ciated with Osteoporotic Hip Fracture in Elderly Korean Women
Based on the National Health Insurance Claims Database 2002–
2004 Value in Health Supporting Information, Table S4 at:
http://www.ispor.org/Publications/value/ViHsupplementary/
ViH12s3_ Kang.asp.
No cost increase was observed between age groups 50 to 54
and 55 to 59 (the youngest age bracket) and between age groups
80 to 84 and85 (the oldest age bracket). In contrast, the middle
age groups, i.e., 55 to 59 years to 75 to 79 years, showed a linear
increase in the per capita costs with every 5-year increase in age.
Discussion
In this study, insurance-covered medical cost of osteoporotic hip
fracture was calculated as KRW3.18 million per patient over a
2-year period after the fracture. Hip fracture patients in Korea
incur considerably lower treatment expenses in the second year
(only 2.6% of that in the ﬁrst year) than in the ﬁrst year after
fracture. This is in sharp contrast with the study results from
other countries. Wiktorowicz et al. [12] has reported that the
medical expenses incurred during the second year after hip frac-
ture were 25% (age group, 65–74 years), 12% (75–84 years),
and 0% (85 years) of the expenses incurred during the ﬁrst year
of the fracture. In a survey conducted in ﬁve European countries,
the direct expenses incurred during the second year ranged from
34% to 73% of those in the ﬁrst year [13]. This result, which is
in sharp contrast to our results, could be attributed to the differ-
ence in the availability of long-term health-care facilities for
fracture patients. In Korea, there is an acute paucity of health-
care facilities for treating elderly patients who develop physical
disabilities after fracture, and no assured insurance beneﬁts are
available. In contrast, most of the elderly fracture patients in
other developed countries are accommodated in long-term
health-care facilities and receive continuous treatment and care.
Another possible explanation could be because of the treatment
gap between the guideline and actual practice regarding recom-
mended osteoporosis screening and treatment after fracture.
Because older women with prior fractures are at a higher risk for
refractures, guidelines recommend pharmacological treatment of
osteoporosis and measurement of bone mineral density after
fracture [14]. Nevertheless, the very low second-year cost esti-
mated in this study implies that the adherence to the guidelines
may not be high among Korean elderly.
It is worth comparing the per capita spending of patients with
hip fracture with that due to other diseases to help understand
the relative economic impact of hip fracture. The average annual
per capita insurance-covered medical expenditure on treatment
of hip fracture during the ﬁrst year of incidence (KRW3.1
million) was comparable to the annual per patient insurance-
covered medical costs of all types of cancer (KRW3.4 million)
and is higher than the direct medical cost for dementia in Korea
(KRW2.6 million) [15,16].
Because this study identiﬁed female hip fracture patients and
estimated direct medical costs by using NHI claims records, it has
an advantage of generalizing the study results to the Korean
population. Nevertheless, because the main objective of insur-
ance claims is reimbursement of medical expenses, the accuracy
of information not directly related to medical reimbursement
might be questionable. For example, when claims records are
used to identify claims derived from the use of medical services
for a speciﬁc disease, the disease code documented in the claims
record is utilized. Nevertheless, if the study inclusion criteria are
based on higher level disease codes, there is a risk of indiscrimi-
nate inclusion of claims with lower level disease codes. Nonethe-
less, because the disease code description in the claims records
submitted by health-care institutions in Korea has not been stan-
dardized; lower or higher level codes might be recorded depend-
ing on the institution or physician in charge, resulting in
inconsistencies. This study tried to minimize the chances of
excluding fractures that match the inclusion criteria; therefore, in
the case of several disease codes, study subjects were selected
based on a higher level disease code.
In Korea, osteoporosis disease codes might be omitted from
the claims records because of the following reasons. First,
osteoporosis may remain undiagnosed, and hence, the patient
might not receive treatment. Second, a patient diagnosed with
osteoporosis might be treated with drugs not covered by the
NHI. Thus, it can be difﬁcult to clearly identify all osteoporosis
patients. Therefore, this study attempted to identify osteoporosis
patients by utilizing osteoporosis disease codes or from claims
records bearing prescriptions for antiosteoporosis drugs at least
once during the 3-year observation period around fracture occur-
rence.
In this study, “high-cost disease” was deﬁned by consulting
the clinicians. For future study, there would be two possible ways
to deﬁne high-cost diseases more solidly. First, the deﬁnition or
choice of high-cost diseases may be based on the diseases with the
actual highest claims after analyzing the NHI claims databases in
Korea. Second, searching the deﬁnition of high-cost disease in the
databases of PubMed or Medline would be another method.
Conclusion
This study estimated the medical expenses incurred by all elderly
female osteoporotic hip fracture patients and by individual
patients during the ﬁrst and second years after fracture occur-
rence in Korea in the recent past. Exploring the economic burden
of osteoporotic hip fracture in the elderly women is expected to
motivate policymakers and clinicians to adopt effective treatment
options from the viewpoints of disease prevention and expendi-
ture control.
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